Keros Therapeutics (KROS) Misses Q2 EPS by 5c

Keros Therapeutics (NASDAQ: KROS) reported Q2 EPS of ($1.45), $0.05 worse than the analyst estimate of ($1.40).

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• RBC Capital Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Sector Perform
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies